Menu
The figure shows homologous recombination repair marker, RAD51 (red), in high-grade serous ovarian cancer tumor cell nuclei (blue).
New tool for tailoring drug treatment in ovarian cancer
Researchers at the Universities of Helsinki and Turku have developed a test to identify those ovarian cancer patients who benefit from traditional platinum-based chemotherapy as well as from a newer…
Exciting R2B funding news
iCAN had a strong showing in Business Finland’s last Research to Business funding round. Four out of eight projects funded at the University of Helsinki were from the iCAN community,…
Potilas-tutkijatapaaminen – aiheena munasarjasyövän tutkimus
In English: iCAN is organizing a series of meetups at Biomedicum, Helsinki. The purpose of these events is to gather patients, interested citizens and researchers together for conversations and to…